Xiaodan Wei
Impact in
-
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Nephrology top 5%
- Chronic Kidney Disease and Diabetes
Papers in
-
- Nanoplatforms for cancer theranostics 19
-
- Nanoparticle-Based Drug Delivery 5
- Co-authors
- Marc Alan Pfeffer (1 shared paper)Lars Køber (1 shared paper)Francesca C. Lawson (1 shared paper)Brian Lee Claggett (1 shared paper)Jeffrey L. Probstfield (1 shared paper)Rafael Díaz (1 shared paper)John J.V. McMurray (1 shared paper)Scott David Solomon (1 shared paper)
- Journals
- Oncotarget (4 papers)Acta Biomaterialia (2 papers)International Journal of Nanomedicine (2 papers)Scientific Reports (2 papers)PLoS ONE (2 papers)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Xiaodan Wei
46 papers receiving 2.8k citations
Xiaodan Wei's Hit Papers
Peers
Comparison fields: 5 of 111
- Endocrinology, Diabetes and Metabolism 1.7k
- Nephrology 150
- Biomaterials 148
- Cardiology and Cardiovascular Medicine 252
- Biomedical Engineering 310
Countries citing papers authored by Xiaodan Wei
This map shows the geographic impact of Xiaodan Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaodan Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaodan Wei more than expected).
Fields of papers citing papers by Xiaodan Wei
This network shows the impact of papers produced by Xiaodan Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaodan Wei. The network helps show where Xiaodan Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaodan Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Hit paper breakdown → | 2015 | 1959 |
| 2 | 2015 | 72 | |
| 3 | 2021 | 63 | |
| 4 | 2024 | 59 | |
| 5 | 2021 | 53 | |
| 6 | 2022 | 50 | |
| 7 | 2022 | 40 | |
| 8 | 2015 | 34 | |
| 9 | 2015 | 32 | |
| 10 | 2024 | 32 | |
| 11 | 2021 | 31 | |
| 12 | 2021 | 29 | |
| 13 | 2022 | 28 | |
| 14 | 2020 | 27 | |
| 15 | 2023 | 27 | |
| 16 | 2018 | 25 | |
| 17 | 2021 | 25 | |
| 18 | 2023 | 24 | |
| 19 | 2016 | 22 | |
| 20 | 2017 | 21 |
About Xiaodan Wei
Xiaodan Wei is a scholar working on Biomedical Engineering, Biomaterials, Oncology, Endocrinology, Diabetes and Metabolism and Dermatology, having authored 49 papers that have together received 2.9k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (19 papers), Nanoparticle-Based Drug Delivery (5 papers), Genetic Associations and Epidemiology (3 papers), Dermatology and Skin Diseases (2 papers), Prostate Cancer Treatment and Research (2 papers), Cytokine Signaling Pathways and Interactions (2 papers), Cancer Immunotherapy and Biomarkers (1 paper) and Hepatitis C virus research (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.7k citations), Nephrology (150 citations), Biomaterials (148 citations), Cardiology and Cardiovascular Medicine (252 citations) and Biomedical Engineering (310 citations). Xiaodan Wei has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Marc Alan Pfeffer, Lars Køber, Francesca C. Lawson, Brian Lee Claggett, Jeffrey L. Probstfield, Rafael Díaz, John J.V. McMurray, Scott David Solomon, Matthew C. Riddle and Eldrin Foster Lewis. Their work appears in journals such as Oncotarget, Acta Biomaterialia, International Journal of Nanomedicine, Scientific Reports and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.